摘要
目的:比较美罗华单药或联合化疗和单用CHOP方案治疗初治的B细胞性非霍奇金淋巴瘤的临床疗效及不良反应。方法:采用同期非随机对照的前瞻性研究方法,将51例初治B细胞淋巴瘤患者分为美罗华组和CHOP组,前组24例,采用美罗华单药或联合化疗;后组27例,单用CHOP方案化疗。3～6疗程后比较2组的疗效及不良反应。结果:美罗华组完全缓解(CR)率83.3%(20/24),总有效率(OR)95.8%(23/24);CHOP组CR率55.6%(15/27),OR率66.7%(18/27),2组疗效差异有统计学意义(P<0.05)。美罗华组2年的总生存率为70.8%,CHOP组为40.7%,美罗华组优于CHOP组(P<0.05)。结论:美罗华治疗初治B细胞淋巴瘤可取得较好疗效,2年生存率高,不良反应能耐受。
Objective：To compare the efficacy of Rituximab with or without chemotherapy and CHOP alone on newly diagnosed patients with B-cell non-Hodgkin lymphoma（NHL）, and to analyze their toxicities. Method.. A total of 51 newly diagnosed patients with B-cell NHL were divided into 2 groups prospectively with concurrent control： 24 cases in Rituximab group were administered Rituximab with or without chemotherapy, the remaining 27 cases in CHOP group were treated with CHOP regimen only. All cases were evaluated after 3-6 courses. Result： The complete remission （CR） rate and totol response rate in Rituximab group were 83.3% （20/24） and 95.8% （23/24） respectively, while those corresponding rates in CHOP group were 55.6%（15/27） and 66.7%（18/27）, respectively. The therapeutic efficacy differences between two groups showed statistical significance（ P 〈0.05）. The 2-year overall survival rate was significantly higer in Rituximab group than in CHOP group（70.8% vs. 40. 7 %, P 〈0.05）. Conclusion：Comparing with CHOP group, Rituximab group showed higher therapeutic effects and 2-year overall survival rate. Rituximab can be used with good tolerance.
出处
《临床血液学杂志》
CAS
2007年第6期326-328,共3页
Journal of Clinical Hematology
